Pediatric Blood & Cancer 2010-07-15

Stanozolol treatment for successful prevention of attacks of severe primary cryofibrinogenemia.

Sule Unal, Fehime Kara, Seza Ozen, Diclehan Orhan, Murat Tuncer, Fatma Gumruk

Index: Pediatr. Blood Cancer 55(1) , 174-6, (2010)

Full Text: HTML

Abstract

Severe essential cryofibrinogenemia is rare in childhood, and both the diagnosis and the management are challenging for pediatricians. An 11-year-old male, who had already lost two digits following cold exposure, was referred after multiple visits to various hospitals and subsequently diagnosed as primary cryofibrinogenemia. His history revealed unresponsiveness to calcium channel blockers, acetyl salicylic acid, pentoxifylline, dextran, and steroids. Stanozolol (2 mg/day, orally) prophylaxis was initiated and no new skin lesions developed following starting this treatment. Some of the newly formed lesions at the onset of stanozolol healed.